Intelligent Bio Solutions Inc. (INBS) Stock Price & Analysis
Intelligent Bio Solutions Inc. (INBS) fell 2.78% to USD 1.75 as of July 25, 2026 at 05:20 UTC, according to Nexqual real-time market data.
INBS last closed at USD 1.8; the session ranged USD 1.72–1.87 on volume of 62,138 shares. Market capitalization is $4.19M, with a 52-week range of USD 1.58–24.9 (NCM). Source: Nexqual, July 25, 2026 at 05:20 UTC.
Key Statistics (as of July 25, 2026 at 05:20 UTC)
| Price | USD 1.75 |
|---|---|
| Change | ▼ 2.78% (down) |
| Previous Close | USD 1.8 |
| Open | USD 1.81 |
| Day Range | USD 1.72 – 1.87 |
| 52-Week Range | USD 1.58 – 24.9 |
| Volume | 62,138 shares |
| Market Cap | $4.19M |
| Exchange | NCM |
Technical Analysis (INBS)
Nexqual's technical model rates INBS "SELL" based on 2 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 05:20 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 26.07 (oversold) |
| vs SMA50 | Below (USD 2.45) |
| MACD | -0.16 (negative) |
Analyst Ratings (INBS)
Wall Street analysts rate INBS "None" based on 1 analysts, with a mean price target of USD 12 (range USD 12–12), per Nexqual as of July 25, 2026 at 05:20 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 12 |
| High Target | USD 12 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (INBS)
| Revenue Estimate | $1.22M |
|---|
Source: Nexqual, July 25, 2026 at 05:20 UTC.
Financials & Fundamentals (INBS)
| Total Revenue | $3.91M |
|---|---|
| Revenue Growth (YoY) | +45.50% |
| Gross Margin | +47.25% |
| Operating Margin | -277.33% |
| Profit Margin | -296.77% |
| ROE | -170.19% |
| Debt / Equity | 21.12 |
| Current Ratio | 2.11 |
| Total Cash | $6.86M |
| Total Debt | $1.85M |
| Free Cash Flow | $-6.49M |
Source: Nexqual, July 25, 2026 at 05:20 UTC.
Financial Health Score (INBS)
Nexqual rates Intelligent Bio Solutions Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 05:20 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $7M cash vs $2M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$11M |
| Efficiency | Critical — ROE -170%, ROA -57.3% |
Ownership (INBS)
| Insider Ownership | +3.57% |
|---|---|
| Institutional Ownership | +8.71% |
| Shares Outstanding | 2.39M |
| Float | 2.17M |
| Short % of Float | +3.57% |
Source: Nexqual, July 25, 2026 at 05:20 UTC.
Leadership (INBS)
Intelligent Bio Solutions Inc. is led by Harry Simeonidis (age 57), President & CEO, per Nexqual as of July 25, 2026 at 05:20 UTC.
| President & CEO | Harry Simeonidis (age 57) |
|---|---|
| Chief Financial Officer | Spiro Kevin Sakiris B.Bus, C.A., Dip Law (age 63) |
| Vice President of Global Quality & Operations | Callistus Sequeira |
| Vice President of Global Sales | Doug Heath |
| Vice President of Marketing | Anna Turkington |
Major Backers & Investors (INBS)
Notable institutional backers of Intelligent Bio Solutions Inc. include Armistice Capital, LLC, Alyeska Investment Group, L.p., Fidelity, according to Nexqual as of July 25, 2026 at 05:20 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Armistice Capital, LLC | 5.44% |
| Alyeska Investment Group, L.p. | 1.59% |
| Fidelity | 0.61% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 1.2% |
| Vanguard Group | 0.65% |
Source: Nexqual, July 25, 2026 at 05:20 UTC.
From Intelligent Bio Solutions Inc.'s Latest SEC 10-K Filing (filed 2025-08-15)
Key Strengths & Strategy (as disclosed to the SEC)
- The Company operates globally with the objective of providing innovative and accessible solutions that improve the quality of life.   Our Testing Platforms   Intelligent Fingerprinting Platform: The Company's current active product is the Intelligent Fingerprinting Platform, which consists of the proprietary portable platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader.
- We completed a 510(k) submission in December 2024, and remain focused on securing FDA 510(k) clearance for the IFP System's opiate test system for codeine in the U.S., which will enable broader use beyond current Forensic Use Only settings.
- Approximately 292 million people used drugs worldwide in 2022, a 20% increase over the previous decade.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CDIO | Cardio Diagnostics Holdings Inc | USD 1.55 | ▼ 7.74% |
| TNON | Tenon Medical, Inc. | USD 0.19 | ▼ 3.65% |
| BDRX | Biodexa Pharmaceuticals plc | USD 1.65 | ▼ 3.51% |
| SPRC | SciSparc Ltd. | USD 5.33 | ▲ 10.12% |
| HSCS | HeartSciences Inc. | USD 2.39 | ▼ 4.4% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 05:20 UTC. This page is informational and not investment advice.